FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof, having CRP receptor antagonist activity. In formula 
(I) R1 denotes C3-C8 alkyl, optionally substituted with hydroxyl; phenyl optionally substituted with 1-3 substitutes selected from halogen, nitro, amino, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, optionally substituted with hydroxyl or C1-C4 alkylamino; naphthyl; C-bonded 5-6-member heteroaryl with 1-2 heteroatoms selected from S, N or O, optionally substituted with C1-C4 alkyl, C1-C4 alkoxy or acetyl; N-bonded 5-member heteroaryl with 1-2 heteroatoms selected from N, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl or phenyl; R2 denotes phenyl, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl, halogenC1-C4alkyl, C1-C4 alkoxy, halogenC1-C4alkoxy, halogen, hydroxy, di(C1-C4 alkyl)amino or di(C1-C4 alkyl)aminocarbonyl; or a heterocyclic group which is pyridyl, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl, C1-C4 alkoxy or di(C1-C4 alkyl)amino; X denotes -NR3-, where R3 denotes C1-C4 alkyl, optionally substituted with hydroxyl, carboxyl or C1-C4 alkoxycarbonyl; Y1 denotes CR3a, where R3a denotes hydrogen, halogen, cyano, hydroxy, C1-C4 alkyl, optionally substituted with hydroxyl or halogen, C1-C4 alkoxy optionally substituted with halogen; Y2 denotes CR3b, where R3b denotes hydrogen or halogen; Y3 denotes N or CR3c, where R3c denotes hydrogen; and Z denotes O or -NR4-, where R4 denotes hydrogen.
EFFECT: invention also pertains to a method of producing compounds of formula (I), a pharmaceutical composition, an inhibiting method, CRF receptor antagonists and use thereof to prepare a medicinal agent.
25 cl, 9 tbl, 163 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
| 6-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780338C2 |
| PYRIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | 2004 |
|
RU2353617C2 |
| SPIROCYCLIC PYRROLOPYRAZINE(PIPERIDINE)AMIDES AS IONIC CHANNELS MODULATORS | 2012 |
|
RU2634900C2 |
| HETEROCYCLIC COMPOUNDS MODULATING ACTIVITY OF CHEMOKINE RECEPTOR, THEIR USING AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2001 |
|
RU2297413C2 |
| HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING | 2001 |
|
RU2289581C2 |
| BENZIMIDAZOLE DERIVATIVES, BASED PHARMACEUTICAL COMPOSITION AND METHODS OF USING THEM | 2008 |
|
RU2456276C2 |
| CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
| BENZIMIDAZOLE SULFONAMIDES DERIVATIVES AS INVERSE AGONISTS ASSOCIATED WITH RETINOIDS OF THE ORPHAN RECEPTOR GAMMA ROR GAMMA (T) | 2015 |
|
RU2738843C2 |
| MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
